Bipolar Disorder Market, By Disorder (Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder), By Drug Class (Mood Stabilizer, Anticonvulsant, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs), By Mechanism of Action (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines), By Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa) – Trends, Analysis and Forecast till 2029

Bipolar Disorder Market accounted for US$ 5.3 billion in 2020 and is estimated to be US$ 6.7 billion by 2030 and is anticipated to register a CAGR of 2.3%

Manic disease or depression is usually defined with the term called Bipolar Disorder Market. It is brain disorder or mental illness that causes unusual shifts in mood and activity level of an individual. Mood episode is characterized by drastic changes in person’s usual mood and their behavior. Depressive and manic episodes are the two type of mood episode. As per the researchers, the person with certain gene are more likely to develop bipolar disease within themselves. An individual suffering from bipolar disorder can be happy, joyful, and energized at a particular moment and can also be sad and depressed the next moment. These kind of mood episodes can hamper the image of an individual at a school or at a job or even in the society.

As the use of smartphones, smartwatches, and wearable devices facilitates accurate detection of a patient’s mood and mental state and environmental data effectively due to innovation and technology is said to be major driving force of this market. Besides the advent of online self-management tools for mental disorders enables timely intervention and better adherence to prescribed treatment. Across the globe, increasing incidence of bipolar disorders is a major factor expected to fuel growth to the global bipolar disorder market over forecast period.

However, the dearth of exact diagnostic methods for the identification of the syndrome/disorder as well as the side effects related to bipolar disorder is projected to hinder the market development. Many of the drugs used in the treatment of bipolar disorder have associated side effects which include addiction of the body to the drug, diabetes and cholesterol issues, blurred vision, damage to the liver, and thyroid, among others which may inhibit the growth of the target market.

Bipolar disorder market is segmented on the basis of disorder, drug class, mechanism of action and region.

On the basis of disorder, the target market is classified into bipolar I disorder, bipolar II disorder, cyclothymic disorder. Bipolar I disorder is a mixed or manic episode; bipolar II disorder is a depression and hypomania; and cyclothymic is a mild depression and hypomania. On the basis of drug class, target market is classified into mood stabilizer, anticonvulsant, antipsychotic drugs, antidepressant drugs, antianxiety drugs. On the basis of mechanism, the target market is divided into serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, beta blockers, benzodiazepines.

 Regional Insights:

On the basis of Region, the bipolar disease market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

North America is the dominating and leading the global bipolar disorder market owing to augmented knowledge and larger accessibility of treatment alternatives. Second dominating region is more likely to be Europe, which is projected to contribute to the development of the global bipolar disorder market based on revenue. The Asia Pacific is expected to be the extremely prospective market with developing countries such as China and India.

The market key players in the bipolar disorder market are AstraZeneca limited., Pfizer Inc., Glaxo SmithKline (GSK) Pvt Lt., Eli Lilly Inc., Janssen Pharmaceuticals, Novartis AG pharmaceutical limited, Allergan Plc., Otsuka Holdings Co. Ltd., and AbbVie Inc.

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
   • PORTER’s
   • Investment Outlook
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for Global Bipolar Disorder Market Strategies
     • Key Questions this Study will Answer

     • By Disorder (Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder)

     • By Drug Class (Mood Stabilizer, Anticonvulsant, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs)

     • By Mechanism of Action (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines)

   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Overview
   • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
   • Y-o-Y Growth Analysis (%), 2020 – 2030
   • Regional Trends
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Regional Analysis
   • Regional Revenue Analysis
   • Regional By segment Analysis
   • Reasons for regional growth
   • Key Player of particular region
   • Countries Include in the report:

1. • • North America (U.S., Canada)
     • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
     • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
     • Latin America (Brazil, Mexico, Rest of Latin America)
     • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
   • Competitive Overview
   • Competitive Benchmarking
   • Market Share Analysis
   • Key Developments In The Global Global Bipolar Disorder Market Market
   • Key Developments: Mergers & Acquisitions
   • Key Developments: Collaboration
   • Key Developments: Contracts & Agreements
   • Key Developments: Expansion
   • Key Developments: Product Developments
2. Company Profiles

• AstraZeneca limited.
• Pfizer Inc.
• Glaxo SmithKline (GSK)
• Eli Lilly Inc.
• Janssen Pharmaceuticals
• Novartis AG pharmaceutical limited
• Allergan Plc
• Otsuka Holdings Co. Ltd.
• AbbVie Inc.

The Last Word

• Future Impact
• About Us
• Contact